Computational Drug Development Strategies to Target HIV-1 - Babajan, B.;Shaik, Noor Ahmad;M., Chaitanya
51,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
26 °P sammeln
  • Broschiertes Buch

In the battle between human antiretroviral drug therapy techniques and HIV-1 microevolution, HIV-1 is currently outpacing human antiretroviral drug therapy techniques: all treatments ultimately end in HIV-1 developing resistance to the treatment. Some scientists believe humans are pushing the microevolution of HIV-1 toward more resistant viruses. For example, some researchers claim that human drug therapies are accelerating retrovirus evolution through drug therapies that select for resistant viruses. Human intervention on HIV-1 evolution through drug therapies has also been accused of being…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
In the battle between human antiretroviral drug therapy techniques and HIV-1 microevolution, HIV-1 is currently outpacing human antiretroviral drug therapy techniques: all treatments ultimately end in HIV-1 developing resistance to the treatment. Some scientists believe humans are pushing the microevolution of HIV-1 toward more resistant viruses. For example, some researchers claim that human drug therapies are accelerating retrovirus evolution through drug therapies that select for resistant viruses. Human intervention on HIV-1 evolution through drug therapies has also been accused of being detrimental to the ultimate goal of finding a permanent cure for HIV-1.
Autorenporträt
Dr. B. Babajan obtained his Ph.D., in Dept. of Biochemistry at Sri Krishnadevarya University. He is currently a Bioinformatic Scientist in PACER-HD at King Abdulaziz University, where he leads a group conducting research into Drug Discovery, SNP analysis, Genome Analysis and Computational Software's Development.